|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Schizophrenia | |||||
| 2 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| Schizophrenia and Disorders with Psychotic Features | |||||
| 3 | Additional drug interventions recognized in this trial | ||||
| Galantamine | |||||
| 4 | More general drug interventions related to this trial | ||||
| Autonomic Agents | |||||
| Central Nervous System Agents | |||||
| Cholinergic Agents | |||||
| Cholinesterase Inhibitors | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Nootropic Agents | |||||
| Parasympathomimetics | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| Johnson &Johnson Pharmaceutical Research &Development, L.L.C. | |||||